2017
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT et. al.Základní údaje
Originální název
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
Autoři
MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT, R. HÁJEK, T. FACON, H. LUDWIG, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSIÑOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S. FENG a M.A. DIMOPOULOS
Vydání
Leukemia, London, Nature Publishing Group, 2017, 0887-6924
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30205 Hematology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 10.023
Organizační jednotka
Lékařská fakulta
UT WoS
000394058700015
Klíčová slova anglicky
2ND-GENERATION PROTEASOME INHIBITOR; STEM-CELL TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; RETREATMENT
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 16. 3. 2018 16:59, Soňa Böhmová
Anotace
V originále
The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with greater than or equal to2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (greater than or equal to2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.